M M Akbar arrested in Hyderabad en-route to Qatar; likely to be grilled by Kerala police

Washington, Jan 12: US president Donald Trump said Saturday the United States was monitoring Iranian demonstrations closely, warning against any new “massacre” as protests broke out after Tehran admitted to shooting down a passenger plane.

Iran said earlier it unintentionally downed a Ukrainian jetliner outside Tehran, killing all 176 people aboard, in an abrupt about-turn after initially saying that it had crashed due to mechanical failure. The firing came shortly after Iran launched missiles at bases in Iraq housing American forces.

President Hassan Rouhani said a military probe into the tragedy had found that “missiles fired due to human error” brought down the Boeing 737, calling it an “unforgivable mistake.”

Trump told Iranians -- in tweets in both English and Farsi -- that he stands by them and is monitoring the demonstrations.

“To the brave, long-suffering people of Iran: I've stood with you since the beginning of my Presidency, and my Administration will continue to stand with you,” he tweeted.

“There can not be another massacre of peaceful protesters, nor an internet shutdown. The world is watching,” he added, apparently referring to an Iranian crackdown on street protests that broke out in November.

“We are following your protests closely, and are inspired by your courage," he said.

The new demonstrations follow an Iranian crackdown on street protests that broke out in November. Amnesty International has said it left more than 300 people dead. Internet access was reportedly cut off in multiple Iranian provinces ahead of memorials planned a month after the protests.

On Saturday evening, police dispersed students who had converged on Amir Kabir University in Tehran to pay tribute to the victims, after some among the hundreds gathered shouted "destructive" slogans, Fars news agency said.

State television reported that students shouted "anti-regime" chants, while the news agency Fars reported that posters of Soleimani had been torn down.

Bengaluru, Apr 27: Former Prime Minister H D Deve Gowda on Monday demanded that the Karnataka government announce a special package for farmers who are on the verge of quitting agriculture as their profession following losses due to the COVID-19 pandemic.

"Please announce special package for the farmers to bail them out of the loss due to the lockdown.

Drop many of the schemes in the budget but don't leave the farmers in distress," Gowda said in his letter to Chief Minister B S Yediyurappa.

The JD(S) supremo said the way relief has been announced for the milk producers by procuring the unsold milk and distributing it to the slum dwellers, the same assistance should be provided to the farmers of the state.

"If you don't come forward to assist the farmers, then they will be forced to sell their land," Gowda cautioned the Chief Minister.

The former prime minister said the farmers are on the verge of falling in the debt trap and may be compelled to take the extreme step of suicide due to the losses.

Gowda said the farmers are unable to sell their crop because they are not getting proper price for their produce and are selling their crop at a throwaway price to minimise their losses.

"In just one month farmers reached the brink of bankruptcy as they are unable to sell the standing crops in lakhs of acres of land," Gowda said.

The JD(S) supremo has been championing the cause of farmers in the state and highlighting their sufferings.

On April 3 Gowda has appealed to Prime Minister Narendra Modi to look into the plight of farmers, labourers and the middle class people due to the lockdown.

"In such times of crisis, we should see to it that there is no disruption in farming activities by ensuring proper marketing channels to agricultural produce, especially perishables.

Only then we can sustain our long battle against this pandemic," Gowda said in a tweet.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.